Xtant Medical entered into a distribution relationship with Vivex Biomedical to commercialize OsteoVive™ viable cell allograft.
Vivex will process the allograft for Xtant’s U.S. distribution, for use in spine and orthopaedic procedures.
Vivex Biomedical’s proprietary process preserves a cell population that includes marrow-isolated adult multilineage inducible (MIAMI) cells, which have demonstrated support for the innate bone healing process.
Xtant and Vivex were named in our 2015 coverage, NASS PREVIEW: A Guide to the Recently-merged in Spine.
Xtant Medical entered into a distribution relationship with Vivex Biomedical to commercialize OsteoVive™ viable cell allograft.
Vivex will process the allograft for Xtant's U.S. distribution, for use in spine and orthopaedic procedures.
Vivex Biomedical’s proprietary process preserves a cell population that includes marrow-isolated adult...
Xtant Medical entered into a distribution relationship with Vivex Biomedical to commercialize OsteoVive™ viable cell allograft.
Vivex will process the allograft for Xtant’s U.S. distribution, for use in spine and orthopaedic procedures.
Vivex Biomedical’s proprietary process preserves a cell population that includes marrow-isolated adult multilineage inducible (MIAMI) cells, which have demonstrated support for the innate bone healing process.
Copy to clipboard 
